Iris Palme
Overview
Explore the profile of Iris Palme including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Streuer A, Jann J, Boch T, Mossner M, Riabov V, Schmitt N, et al.
Ann Hematol
. 2024 Feb;
103(4):1221-1233.
PMID: 38413410
In low-risk Myelodysplastic Neoplasms (MDS), increased activity of apoptosis-promoting factors such as tumor necrosis factor (TNFα) and pro-apoptotic Fas ligand (CD95L) have been described as possible pathomechanisms leading to impaired...
2.
Riabov V, Xu Q, Schmitt N, Streuer A, Ge G, Bolanos L, et al.
Haematologica
. 2023 Nov;
109(5):1426-1438.
PMID: 37916386
Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMA) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a...
3.
Altrock E, Sens-Albert C, Hofmann F, Riabov V, Schmitt N, Xu Q, et al.
Stem Cell Res Ther
. 2023 Jun;
14(1):156.
PMID: 37287056
Background: Robust and reliable in vitro and in vivo models of primary cells are necessary to study the pathomechanisms of Myelodysplastic Neoplasms (MDS) and identify novel therapeutic strategies. MDS-derived hematopoietic...
4.
Xu Q, Streuer A, Jann J, Altrock E, Schmitt N, Flach J, et al.
Nat Commun
. 2023 Mar;
14(1):1497.
PMID: 36932114
Limited response rates and frequent relapses during standard of care with hypomethylating agents in myelodysplastic neoplasms (MN) require urgent improvement of this treatment indication. Here, by combining 5-azacytidine (5-AZA) with...
5.
Xu Q, Altrock E, Schmitt N, Streuer A, Rapp F, Nowak V, et al.
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36675239
The erythroferrone gene (), also termed , belongs to the C1q tumor necrosis factor-related protein (CTRP) family. Despite multiple reports about the involvement of CTRPs in cancer, the role of...
6.
Altrock E, Sens-Albert C, Jann J, Flach J, Riabov V, Schmitt N, et al.
Exp Hematol
. 2021 Dec;
107:38-50.
PMID: 34952140
Patient-derived xenograft (PDX) models have emerged as versatile preclinical platforms for investigation of functional pathomechanisms in myelodysplastic syndromes (MDS) and other myeloid neoplasms. However, despite increasingly improved methodology, engraftment efficiencies...
7.
Jann J, Mossner M, Riabov V, Altrock E, Schmitt N, Flach J, et al.
Nat Commun
. 2021 Oct;
12(1):6170.
PMID: 34697318
The bone marrow (BM) stroma in myeloid neoplasms is altered and it is hypothesized that this cell compartment may also harbor clonal somatically acquired mutations. By exome sequencing of in...
8.
Schmitt N, Jann J, Altrock E, Flach J, Danner J, Uhlig S, et al.
Leukemia
. 2021 Jun;
36(1):236-247.
PMID: 34172896
Preclinical research of myelodysplastic syndromes (MDSs) is hampered by a lack of feasible disease models. Previously, we have established a robust patient-derived xenograft (PDX) model for MDS. Here we demonstrate...
9.
Riabov V, Mossner M, Stohr A, Jann J, Streuer A, Schmitt N, et al.
Br J Haematol
. 2021 Jan;
192(5):879-891.
PMID: 33486765
Ineffective erythropoiesis and iron overload are common in myelodysplastic syndromes (MDS). Erythroferrone (ERFE) and growth/differentiation factor 15 (GDF15) are two regulators of iron homeostasis produced by erythroid progenitors. Elevated systemic...
10.
Flach J, Jann J, Knaflic A, Riabov V, Streuer A, Altrock E, et al.
Haematologica
. 2020 Oct;
106(11):2906-2917.
PMID: 33054116
Somatic mutations in genes coding for splicing factors, e.g. SF3B1, U2AF1, SRSF2, and others are found in approximately 50% of patients with Myelodysplastic Syndromes (MDS). These mutations have been predicted...